ArticleJournal of clinical medicine2026
Drug Safety and Polypharmacy Signals in Ibrutinib-Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Age- and Sex-Specific FAERS Analysis of CYP3A Modifier and Antithrombotic Co-Exposure.
Velizar ShivarovPubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.